About Us

GeneCentric Company Overview

GeneCentric Therapeutics is applying proprietary technology to identify drug responder populations that enable the development of precision cancer drugs while improving patient outcomes. Our initial approach applies our Cancer Subtype Platform (CSP®) to parse the complexity of tumor biology and generate genomic signatures. This approach yields high-resolution cancer subtypes with the potential to function as universal biomarkers for susceptibility to immune-based, targeted and other therapies. In commercializing our technology through strategic collaborations with pharmaceutical and biotech companies, we are defining responder populations based on subtypes throughout the drug development cycle.

Mike Milburn

Dr. Michael V. Milburn, PhD

Chief Executive Officer and President
































Dr. Myla Lai-Goldman, MD

Founder & Executive Chairperson
































Walter M. Capone, MBA

Chief Business Officer
































Dr. Joel R. Eisner, PhD

Sr. Vice President - Clinical & Corporate Development
































Chenyqua Shepard, CPA

Vice President, Finance
































Greg Mayhew, DrPH

Director of Bioinformatics
































Yoichiro Shibata, PhD

Senior Bioinformatics Scientist
































John Guo

John Guo, PhD

Senior Bioinformatics Scientist
































Josh Uronis, PhD

Laboratory Director
































Jeff Burdine

Sr. Director Information Technology
































Dr. Myla Lai-Goldman, MD

Founder & Executive Chairperson

Dr. Arnold J. Levine, Phd

Director

Ellen Lubman

Director

Mike Milburn

Dr. Michael V. Milburn, PhD

Chief Executive Officer and President

Dr. Charles M. Perou, PhD

Founder and Director

Clay Thorp

Director

Dr. David Neil Hayes, MD MPH MS

Founder

Dr. Charles M. Perou, PhD

Founder and Director

Dr. Myla Lai-Goldman, MD

Founder & Executive Chairperson

Making News: Our Latest Progress, Partnerships and Impact

GeneCentric Therapeutics Presents First Data on Novel Response Signatures to Treatment in Muscle Inv ...

LEARN MORE

Fibroblast growth factor receptor status and response to immune checkpoint inhibition in metastatic ...

LEARN MORE

GeneCentric Collaborators from UNC Lineberger Comprehensive Cancer Center Present on Urothelial Canc ...

LEARN MORE